Switch theme
Sign up to access all valuation multiples
Bumrungrad Hospital PCL operates a private hospital business in Bangkok. It is a healthcare provider in Thailand providing complete healthcare services for both outpatients and inpatients. The company is the owner and operator of multiple healthcare-related entities. The company has only one main reportable operating segment, which is the hospital and health care center business, and the geographical area of its operations is Thailand.
1980
4.2K+
LTM Revenue $784M
LTM EBITDA $309M
$3.1B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Bumrungrad Hospital has a last 12-month revenue (LTM) of $784M and a last 12-month EBITDA of $309M.
In the most recent fiscal year, Bumrungrad Hospital achieved revenue of $784M and an EBITDA of $321M.
Bumrungrad Hospital expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Bumrungrad Hospital valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $784M | XXX | $784M | XXX | XXX | XXX |
| Gross Profit | $403M | XXX | $403M | XXX | XXX | XXX |
| Gross Margin | 51% | XXX | 51% | XXX | XXX | XXX |
| EBITDA | $309M | XXX | $321M | XXX | XXX | XXX |
| EBITDA Margin | 39% | XXX | 41% | XXX | XXX | XXX |
| EBIT | $276M | XXX | $280M | XXX | XXX | XXX |
| EBIT Margin | 35% | XXX | 36% | XXX | XXX | XXX |
| Net Profit | $234M | XXX | $237M | XXX | XXX | XXX |
| Net Margin | 30% | XXX | 30% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Bumrungrad Hospital's stock price is THB 146 (or $4).
Bumrungrad Hospital has current market cap of THB 116B (or $3.5B), and EV of THB 102B (or $3.1B).
See Bumrungrad Hospital trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3.1B | $3.5B | XXX | XXX | XXX | XXX | $0.28 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Bumrungrad Hospital has market cap of $3.5B and EV of $3.1B.
Bumrungrad Hospital's trades at 4.0x EV/Revenue multiple, and 9.7x EV/EBITDA.
Equity research analysts estimate Bumrungrad Hospital's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Bumrungrad Hospital has a P/E ratio of 15.1x.
See valuation multiples for Bumrungrad Hospital and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3.5B | XXX | $3.5B | XXX | XXX | XXX |
| EV (current) | $3.1B | XXX | $3.1B | XXX | XXX | XXX |
| EV/Revenue | 4.0x | XXX | 4.0x | XXX | XXX | XXX |
| EV/EBITDA | 10.1x | XXX | 9.7x | XXX | XXX | XXX |
| EV/EBIT | 11.3x | XXX | 11.1x | XXX | XXX | XXX |
| EV/Gross Profit | 7.7x | XXX | n/a | XXX | XXX | XXX |
| P/E | 15.1x | XXX | 14.9x | XXX | XXX | XXX |
| EV/FCF | 17.3x | XXX | 13.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialBumrungrad Hospital's last 12 month revenue growth is 3%
Bumrungrad Hospital's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $29K for the same period.
Bumrungrad Hospital's rule of 40 is 41% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Bumrungrad Hospital's rule of X is 46% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Bumrungrad Hospital and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 3% | XXX | 3% | XXX | XXX | XXX |
| EBITDA Margin | 39% | XXX | 41% | XXX | XXX | XXX |
| EBITDA Growth | 1% | XXX | 1% | XXX | XXX | XXX |
| Rule of 40 | 41% | XXX | 44% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 46% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $29K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 3% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 16% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Burjeel Holdings | XXX | XXX | XXX | XXX | XXX | XXX |
| PureHealth | XXX | XXX | XXX | XXX | XXX | XXX |
| Integral Diagnostics | XXX | XXX | XXX | XXX | XXX | XXX |
| Ramsay Health | XXX | XXX | XXX | XXX | XXX | XXX |
| Athens Medical Centre | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Bumrungrad Hospital acquired XXX companies to date.
Last acquisition by Bumrungrad Hospital was XXXXXXXX, XXXXX XXXXX XXXXXX . Bumrungrad Hospital acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Bumrungrad Hospital founded? | Bumrungrad Hospital was founded in 1980. |
| Where is Bumrungrad Hospital headquartered? | Bumrungrad Hospital is headquartered in Thailand. |
| How many employees does Bumrungrad Hospital have? | As of today, Bumrungrad Hospital has 4.2K+ employees. |
| Is Bumrungrad Hospital publicy listed? | Yes, Bumrungrad Hospital is a public company listed on BKK. |
| What is the stock symbol of Bumrungrad Hospital? | Bumrungrad Hospital trades under BH ticker. |
| When did Bumrungrad Hospital go public? | Bumrungrad Hospital went public in 1989. |
| Who are competitors of Bumrungrad Hospital? | Similar companies to Bumrungrad Hospital include e.g. Burjeel Holdings, PureHealth, Integral Diagnostics, Ramsay Health. |
| What is the current market cap of Bumrungrad Hospital? | Bumrungrad Hospital's current market cap is $3.5B |
| What is the current revenue of Bumrungrad Hospital? | Bumrungrad Hospital's last 12 months revenue is $784M. |
| What is the current revenue growth of Bumrungrad Hospital? | Bumrungrad Hospital revenue growth (NTM/LTM) is 3%. |
| What is the current EV/Revenue multiple of Bumrungrad Hospital? | Current revenue multiple of Bumrungrad Hospital is 4.0x. |
| Is Bumrungrad Hospital profitable? | Yes, Bumrungrad Hospital is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Bumrungrad Hospital? | Bumrungrad Hospital's last 12 months EBITDA is $309M. |
| What is Bumrungrad Hospital's EBITDA margin? | Bumrungrad Hospital's last 12 months EBITDA margin is 39%. |
| What is the current EV/EBITDA multiple of Bumrungrad Hospital? | Current EBITDA multiple of Bumrungrad Hospital is 10.1x. |
| What is the current FCF of Bumrungrad Hospital? | Bumrungrad Hospital's last 12 months FCF is $180M. |
| What is Bumrungrad Hospital's FCF margin? | Bumrungrad Hospital's last 12 months FCF margin is 23%. |
| What is the current EV/FCF multiple of Bumrungrad Hospital? | Current FCF multiple of Bumrungrad Hospital is 17.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
